Navigation Links
Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Date:8/19/2007

Management to Make Two Presentations on the Topic of Drug Repurposing and

Indian Clinical Trial Strategy

MORRISTOWN, N.J., Aug. 16 /PRNewswire/ -- Vicus Therapeutics, Inc., an oncology-focused, clinical-stage biopharmaceutical company, announced today that Chief Executive Officer, John Maki, and Chief Scientific Officer, Frederic Young, Ph.D., will each present at the 234th American Chemical Society National Meeting on Sunday, August 19, 2007. The Meeting is being held at the Boston Convention & Exhibition Center in Boston, MA.

Dr. Young will present "Hypothesis-driven Drug Repurposing Based on a Novel Systems Biology Approach," including a discussion of Vicus' complexity theory-based drug repurposing approach in creating a pipeline of product candidates for the treatment of important unmet medical needs. The Company's approach can be applied to the discovery of product candidates for any indication, including cancer cachexia, a metabolic disorder, mucositis, a wound healing disorder, and cancer fatigue, a CNS disorder. The specific application of this method will be discussed in the context of the Company's lead compound, VT-122. Dr. Young's presentation is scheduled for 11:45 a.m.

Mr. Maki's presentation, entitled "Synergistic Advantages of Drug Repurposing and Clinical Trial Off-shoring in India", will include a discussion of the unique synergistic advantages of drug re-profiling and off- shoring, as well as an overview of the steps necessary to realize such advantages. Specifically, Mr. Maki will provide highlights from the Company's ongoing Phase 2 clinical trial of VT-122 for cancer cachexia, now being conducted in the U.S. and India. In addition, he will review recent changes by the Drug Controller General of India (DCGI, the Indian FDA-regulatory equivalent), Indian clinical research infrastructure, and the acceptance of Indian data by the U.S. Food & Drug Administration (FDA) that is currently driving the expl
'/>"/>

SOURCE Vicus Therapeutics

Copyright©2007 PR Newswire.

Page: 1 2 3

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
3. Wisconsin firms to present at Cleantech venture capital event
4. New Sonic Foundry search engine finds words, phrases in video presentations
5. Lone Wisconsin firm to present at InvestMidwest
6. Sonic Foundry creates search engine for 7,000 expert video presentations
7. InvestMidWest calls for business presentations
8. Wicab to present BrainPort at Boston conference
9. Three more Wisconsin firms to present at venture forum
10. Six Wisconsin firms to present at BIO Mid-America VentureForum
11. New Health and Human Services representative for Midwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... October 30, 2014 Investor-Edge has ... (NYSE MKT: ONVO), Medivation Inc. (NASDAQ: MDVN ... Biologics Inc. (NYSE MKT: SYN), and Ironwood Pharmaceuticals Inc. ... be accessed at: http://investor-edge.com/register . On ... 4,549.23, down 0.33%, the Dow Jones Industrial Average declined ...
(Date:10/30/2014)... Chicago, Illinois (PRWEB) October 30, 2014 ... Regenerative and Cellular Medicine Showcase in Chicago, leading ... and Orthopedic Surgeon, Dr. Wade McKenna presented talks ... Effectiveness and Orthopedic Surgical Applications For Stem Cells. ... of amniotic membrane and the properties of AlphaGEMS ...
(Date:10/30/2014)... October 30, 2014 Spartan Bioscience announced ... RX CYP2C19 System . It detects CYP2C19 genetic mutations ... swab. , The Spartan RX CYP2C19 System is the ... been approved in Canada. Due to the system’s ease ... be used by healthcare professionals such as doctors, nurses, ...
(Date:10/30/2014)... CARLSBAD, Calif. , Oct. 30, 2014 Isis ... antisense therapeutics, today announced that management will present a company ... 2014 at 8:30 a.m. ET in Boston, MA. ... will be available on the "Investors & Media" section of ... available on the Isis website within 48 hours and will ...
Breaking Biology Technology:Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2
... WALTHAM, Mass., June 12 Repligen Corporation,(Nasdaq: RGEN ... fiscal,year 2008, ended March 31, 2008. Total revenue for ... $14,074,000 for fiscal year 2007,ended March 31, 2007, an ... consisted primarily of Protein A and SecreFlo(R) product revenue., ...
... Bulletin Board: RPTP), today announced that Ted Daley, President ... the 2008 BIO International Convention to be held June ... Diego, CA., Mr. Daley,s 15-minute corporate overview will ... in room 4 of the CNS/Neurology track., For ...
... Therapeutics, Inc.,(Nasdaq and MTA: CTIC) today announced that a ... newly issued 15% Convertible,Senior Notes due 2011, with an ... to purchase approximately 14.6 million shares of common stock,with ... transaction constitutes a partial exercise of a previously granted,warrant ...
Cached Biology Technology:Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 2Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 3Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 4Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 5Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 6Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 7Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 8Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention 2Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention 3Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention 4Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor 2
(Date:10/30/2014)... German . ... to behave socially? This is one of the central ... studies assumed that it is almost impossible to control ... Planck Institute for Evolutionary Biology have now demonstrated that ... cooperative behaviour of others. However, the possibilities available to ...
(Date:10/30/2014)... North Carolina State University researchers have developed a suite ... between dogs and humans, which has applications in everything ... our pets. , "We,ve developed a platform for computer-mediated ... to new avenues for interpreting dogs, behavioral signals and ... Dr. David Roberts, an assistant professor of computer science ...
(Date:10/29/2014)... oil and gas production are well over recommended levels ... access journal Environmental Health . High levels of ... is the first to be based on community sampling ... be used to supplement official air-quality monitoring programs. , ... not readily flow to the surface. This is because ...
Breaking Biology News(10 mins):Together we are strong -- or insufferable 2Together we are strong -- or insufferable 3Together we are strong -- or insufferable 4New tech aims to improve communication between dogs and humans 2Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3
... at Duke University and the U.S. Geological Survey (USGS) ... production in Arkansas. "Our results show no discernible ... gas drilling and hydraulic fracturing in this region," said ... Duke,s Nicholas School of the Environment. ...
... become stiff after middle age, a new study has revealed., ... compensate for the effects of obesity. But after middle age, ... body fat rises potentially increasing the risk of dying ... of body fat may be related to the total number ...
... emerged in China in February 2013, and is associated ... than 100 human cases of infection, including at least ... cases of infection were described in Hangzhou, Zhejiang Province, ... were similar to the previously reported cases in China. ...
Cached Biology News:Groundwater unaffected by shale gas production in Arkansas 2Body fat hardens arteries after middle age 2Evidence of host adaptation of avian-origin influenza A virus 2